Characterizing human mesenchymal stromal cells' immune-modulatory potency using targeted lipidomic profiling of sphingolipids.

Journal Article (Journal Article)

Cell therapies are expected to increase over the next decade owing to increasing demand for clinical applications. Mesenchymal stromal cells (MSCs) have been explored to treat a number of diseases, with some successes in early clinical trials. Despite early successes, poor MSC characterization results in lessened therapeutic capacity once in vivo. Here, we characterized MSCs derived from bone marrow (BM), adipose tissue and umbilical cord tissue for sphingolipids (SLs), a class of bioactive lipids, using liquid chromatography/tandem mass spectrometry. We found that ceramide levels differed based on the donor's sex in BM-MSCs. We detected fatty acyl chain variants in MSCs from all three sources. Linear discriminant analysis revealed that MSCs separated based on tissue source. Principal component analysis showed that interferon-γ-primed and unstimulated MSCs separated according to their SL signature. Lastly, we detected higher ceramide levels in low indoleamine 2,3-dioxygenase MSCs, indicating that sphingomyelinase or ceramidase enzymatic activity may be involved in their immune potency.

Full Text

Duke Authors

Cited Authors

  • DeVeaux, SA; Ogle, ME; Vyshnya, S; Chiappa, NF; Leitmann, B; Rudy, R; Day, A; Mortensen, LJ; Kurtzberg, J; Roy, K; Botchwey, EA

Published Date

  • June 2022

Published In

Volume / Issue

  • 24 / 6

Start / End Page

  • 608 - 618

PubMed ID

  • 35190267

Electronic International Standard Serial Number (EISSN)

  • 1477-2566

Digital Object Identifier (DOI)

  • 10.1016/j.jcyt.2021.12.009


  • eng

Conference Location

  • England